ArticlePLoS neglected tropical diseases2026
Luciferase unleashed: Lighting the path to vaccine approval using a novel high-throughput chikungunya virus neutralization assay.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chikungunya virus (CHIKV) neutralization assays, which measure virus-neutralizing activity, play a pivotal role in evaluating vaccine effectiveness and monitoring immunity. As CHIKV continues to spread beyond endemic tropical regions, causing more frequent outbreaks and debilitating disease, it remains a serious global health concern. Vaccination can help alleviate these burdens by inducing neutralizing antibodies, which are also produced following natural infection. Neutralizing antibodies can prevent virus infection and are considered a key correlate of protection against disease caused by CHIKV. Accurate assessment of neutralizing antibodies is therefore essential for both vaccine evaluation and public health surveillance. This work introduces a validated luciferase-based high-throughput CHIKV neutralization assay (CHIKV-luc NT80) for quantifying serum neutralizing antibodies. The assay uses a genetically engineered reporter virus (CHIKV181/25-luc) that expresses luciferase, allowing in vitro viral infectivity to be measured using luminescence rather than manual plaque counting. Compared to the traditional plaque reduction neutralization test (PRNT), this method is faster, easier, more reproducible, and better suited for large-scale clinical studies associated with a high biological sample burden, due to its scalability. The use of a stringent 80% neutralization titer threshold (NT80) also provides a more stringent measure of antibodies compared to conventional NT50 values. The assay was compared to other methods, having high concordance (r ≈ 0.9) and low bias (≤15%), supporting its analytical reliability, qualified for phase 2 clinical trials, and validated for phase 3 clinical sample testing. The assay contributed to the establishment of the first World Health Organization International Standard for anti-CHIKV (code number 1502/19), and its results harmonized well with other virus neutralization methods. Neutralization titer results from preclinical and clinical serum sample testing supported the characterization of a surrogate threshold of protection, and licensure of VIMKUNYA (CHIKV virus-like particle [VLP] vaccine).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.